Guillain-Barré syndrome following zimeldine treatment.
Thirteen cases of the Guillain-Barré syndrome are reviewed, all occurring with a similar relationship to recent commencement of treatment with the antidepressive drug zimeldine. The risk of developing Guillain-Barré syndrome was increased about 25-fold among patients receiving zimeldine, as compared with the natural incidence of the disorder. The cases described provide strong evidence that Guillain-Barré syndrome may occur as a specific, probably immunologically mediated, complication of drug therapy.
Fagius
J
J
Osterman
P O
PO
Sidén
A
A
Wiholm
B E
BE
D000368:Aged; D003866:Depressive Disorder / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011129:Polyradiculoneuropathy / Q000139:chemically induced*; D012306:Risk; D015031:Zimeldine / Q000009:adverse effects* / Q000627:therapeutic use
D015031:Zimeldine